Antibodies for
Immunohistochemistry
Fascin (55k-2)
Mouse Monoclonal Antibody
Cat. No. Description
Volume
45209 IMPATH Fascin RTU M (55k-2)
50 Tests
44288 Fascin RTU M (55K-2)
7 ml Ready To Use
44598 Fascin 0,1 M (55k-2)
100 µl liquid Concentrated
44599 Fascin 1 M (55k-2)
1 ml liquid Concentrated
Product Specifications
Designation
IVD
Reactivity
Paraffin
Visualization
Cytoplasmic
Control
Hodgkin Lymphoma
Stability
Up to 36 mo. at 2-8°C
Isotype
IgG
1
Manual Protocol*
• Pretreatment: Heat Induced Epitope
Retrieval (HIER)
• Primary Antibody Incubation Time:
10-30min @ 25-37°C
• 2-step polymer detection
*Please refer to product insert for complete protocol.
ImPath Protocol*
• Dewax: Dewax Solution 2 (DS2)
• Pretreatment: Retrieval Solution pH 9.0
(TR1) 32min @ 98-103°C
• Primary Antibody Incubation Time:
10-90min @ 25-37°C
• HRP Polymer (Universal) or AP Polymer
(Universal) for 12 min
*Please refer to product insert for complete protocol.
Product Description
Anti-fascin is a very sensitive marker for Reed-Sternberg cells and variants in nodular sclerosis, mixed cellularity, and lymphocyte depletion
Hodgkin disease. It is uniformly negative in lymphoid cells, plasma cells, and myeloid cells. Anti-fascin is positive in dendritic cells. This marker
may be helpful to distinguish between Hodgkin lymphoma and non-Hodgkin lymphoma in difficult cases. Also, the lack of expression of fascin
in the neoplastic follicles in follicular lymphoma can be helpful in distinguishing these lymphomas from reactive follicular hyperplasia in which the
number of follicular dendritic cells is normal or increased. Anti-fascin has been suggested as a prognostic marker in neuroendocrine neoplasms
of the lung as well as in ovarian cancer.
Hodgkin vs. Non-Hodgkin Lymphomas
Fascin CD79a CD15
CD30 Granzyme
B
BCL6
PU.1
MUM1 ALK-1
EMA
Hodgkin Lymphoma,
Classic
+
-
+
+
-
-
-
+
-
-
Hodgkin Lymphoma,
Nodular Lymphocyte
Predominant
-
+
-
-
-
+
+
-/+
-
+
T-cell Rich LBCL
-
+
-
-
-
+
-
+
-
-
Anaplastic Large Cell
Lymphoma
-
-
-
+
+
+/-
-
-
+
+
Reference
1. Pincus GS, et al. American Journ of Path. 150(2):543-562.
2. Pelosi G, et al. Lung Cancer. 2003 Nov; 42(2):203-13.
3. Goncharuk VN, et al. J Cutan Pathol. 2002 Aug; 29(7):430-8.
4. Kempf W, et al. J Cutan Pathol. 2002 May; 29(5):295-300.
5. Kraus MD, et al. Am J Dermatopathol. 2001 Apr; 23(2):104-11.
6. Hu W, et al. Clin Exp Metastasis. 2000; 18(1):83-8.
7. Chu Pg Ann. Diagn Pathol. 1999 Apr; 3(2):104-33.
118
